Gene Expression Signatures Identify Novel Therapeutics for Metastatic Pancreatic Neuroendocrine Tumors.

Aaron T ScottMichelle WeitzPatrick J BrehenyPo Hien EarBenjamin DarbroBart J BrownTerry A Braun Guiying LiShaikamjad UmesalmaCourtney A KaemmerChandra K Maharjan Dawn E QuelleAndrew M BellizziChandrikha ChandrasekharanJoseph S DillonThomas M O'DorisioJames R Howe

Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2020)

We employed a complementary bioinformatics approach to identify novel therapeutics for pNETs by analyzing gene expression in metastatic tumors. The potential utility of these drugs was confirmed by in vitro cytotoxicity assays, suggesting drugs targeting MEK and TOP2A may be highly efficacious against metastatic pNETs. This is a promising strategy for discovering more effective treatments for patients with pNETs.

Keyphrases

gene expression
squamous cell carcinoma
small cell lung cancer
neuroendocrine tumors
dna methylation
small molecule
high throughput
genome wide
cancer therapy
cell proliferation
climate change
risk assessment
pi k akt
single cell